A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Phase 1
210
about 4.7 years
18+
20 sites in CA, FL, HI +10
What this study is about
Researchers are testing a treatment with valemetostat tosylate and DXd ADCs for people with advanced solid tumors. The trial will start with a dose-escalation phase to determine the best dosage, followed by a dose-expansion phase to further evaluate safety and tolerability.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dato-DXd
- 2.Take T-DXd
- 3.Take Valemetostat tosylate
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (Part 1 Dose Escalation), Objective Response Rate Based on Investigator Assessment (Part 2 Dose Expansion)
Secondary: Duration of Response (DoR), Number of Participants Reporting Treatment-emergent Adverse Events (Part 2 Dose Expansion), Objective Response Rate Based on Investigator Assessment (Part 1 Dose Escalation), Overall Survival, Progression-free Survival
Oncology